ArticleDiscover oncology2026
Development and validation of a four-gene prognostic signature derived from disulfidptosis- and cuproptosis-related genes in oral squamous cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisulfidptosis and cuproptosis are recently identified forms of regulated cell death whose component genes may harbor prognostic information in oral squamous cell carcinoma (OSCC). However, no validated multi-gene prognostic signature derived from these pathways has been established.
methodsDifferentially expressed genes from two GEO discovery cohorts (GSE30784 and GSE37991) were intersected with 28 disulfidptosis- and cuproptosis-related genes. A LASSO-Cox model was developed in a TCGA oral HNSC training cohort (n = 268) and validated in GSE41613 (n = 97), GSE65858 (n = 270), and GSE42743 (n = 55). An extended clinical-genomic model incorporating age, AJCC stage, histological grade, alcohol use, radiation, and chemotherapy was evaluated in a complete-case subcohort (n = 212). Single-cell RNA-seq data (GSE103322; 5,902 cells) were analyzed to characterize hub gene expression across cell types. Hub gene expression was validated by qRT-PCR and ELISA in OSCC cell lines.
resultsA four-gene signature (CDKN2A, FLNA, GLS, TLN1) was identified. The risk score was an independent prognostic factor (HR = 1.36 per SD, 95% CI: 1.08-1.72, P = 0.009) after adjustment for six clinical covariates. The extended combined model achieved a C-index of 0.669 and a 5-year AUC of 0.805, outperforming the extended clinical model (C-index 0.650; 5-year AUC 0.722) and gene-only model (C-index 0.563; 5-year AUC 0.684). The signature achieved significance in GSE41613 (P = 0.046, HR = 1.81) and GSE65858 (P = 0.0013, HR = 1.99), with a concordant trend in GSE42743 (P = 0.079, HR = 2.10). Single-cell analysis showed that CDKN2A was preferentially expressed in malignant cells, while FLNA and TLN1 were enriched in fibroblasts, consistent with ECM-mediated tumor-stromal crosstalk. CellChat revealed that high-activity malignant cells exhibited enhanced LAMININ, COLLAGEN, and THBS signaling. qRT-PCR and ELISA confirmed upregulation of all four hub genes in CAL-27 and SCC-9 cells (P < 0.01).
conclusionsA four-gene prognostic signature derived from disulfidptosis- and cuproptosis-related genes provides independent prognostic value in OSCC and improves stratification when combined with standard clinical variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.